Our co-founders Dr. Joe Loscalzo and Dr. Albert-Laszlo Barabasi pioneered the building of the map of human biology – the Human Interactome – that explains how proteins expressed from genes interact to cause specific disease phenotypes, providing the wiring diagram needed to interpret dynamic molecular data from patients to determine an individual’s unique disease biology.Science publications
Human Genome Project completed.
Our founders Drs. Joseph Loscalzo and Laszlo Barabasi begin building the map of human disease biology that explains how proteins expressed from the human genome interact to cause specific diseases.
The map grows to cover 89% of all proteins in human cells, revealing the underlying biological processed causing many of the most common and difficult to treat diseases.
Scipher Medicine is founded.
Research begins to develop predictive drug response tests.
Scipher applies its research to develop a blood test for predicting drug response to anti-TNF therapies, after months of researching and surveying the healthcare system to identify significant clinical and financial pain points.
September: Scipher completes its Series A funding led by Khosla Ventures.
December: Scipher completes the observational study for its anti-TNF response test in rheumatoid arthritis.
United HealthGroup invests into Scipher.
PrismRA study reads out positive and Scipher launches the test commercially.
Signs pharma deal with Galapagos to develop targets that are specific to biologically similar sub populations of patients.